Surviving motoneurons undergo dendritic atrophy after spinal cord injury (SCI), suggesting an important therapeutic target for neuroprotective strategies to improve recovery of function after SCI. Our previous studies showed that phospholipase A 2 (PLA 2 ) may play an important role in the pathogenesis of SCI. In the present study, we investigated whether blocking cPLA 2 pharmacologically with arachidonyl trifluoromethyl ketone (ATK) or genetically using cPLA 2 knockout (KO) mice attenuates motoneuron atrophy following SCI. C57BL/6 mice received either sham or contusive SCI at the T10 level. At 30 min after SCI, mice were treated with ATK or vehicle. Four weeks later, motoneurons innervating the vastus lateralis muscle of the quadriceps were labeled with cholera toxin-conjugated horseradish peroxidase, and dendritic arbors were reconstructed in three dimensions. Soma volume, motoneuron number, lesion volume, and tissue sparing were also assessed, as were muscle weight, fiber cross-sectional area, and motor endplate size and density. ATK administration reduced percent lesion volume and increased percent volume of spared white matter compared to the vehicle-treated control animals. SCI with or without ATK treatment had no effect on the number or soma volume of quadriceps motoneurons. However, SCI resulted in a decrease in dendritic length of quadriceps motoneurons in untreated animals, and this decrease was completely prevented by treatment with ATK. Similarly, the vastus lateralis muscle weights of untreated SCI animals were smaller than those of sham-surgery controls, and these reductions were prevented by ATK treatment. No effects on fiber cross-sectional areas, motor endplate area or density were observed across treatment groups. Remarkably, genetically deleting cPLA 2 in cPLA 2 KO mice attenuated dendritic atrophy after SCI. These findings suggest that after SCI, cord tissue damage and regressive changes in motoneuron and muscle morphology can be reduced by inhibition of cPLA 2 , further supporting a role for cPLA 2 as a neurotherapeutic target for SCI treatment.
Introduction
Traumatic spinal cord injuries are prevalent in the United States, where more than 11,000 people per year survive a spinal cord injury (SCI). Of these, around 45% suffer from spinal motoneuron lesions, and this number rises to around 95% for those with lumbar or sacral injuries 1 . The pathophysiology of SCI involves both immediate and secondary effects. After the initial trauma, a protracted period of progressive damage occurs, causing spreading of the lesion and further segmental destruction. A variety of mechanisms contribute to this progressive secondary injury, including excitotoxicity 2 , free radical generation 3 , and inflammation 4 , resulting in the death of motoneurons, interneurons, and glial cells at the lesion site. Caudal to the lesion, surviving motoneurons respond to injury with marked dendritic retraction 5 . This secondary dendritic atrophy is likely responsible for at least some of the movement deficits and reduces the excitability of the remaining motoneurons 6 . The target musculature of these motoneurons is also affected, with reductions in weight and fiber cross-sectional fiber diameter 5 .
Given that we currently lack the technology to replace dead motoneurons, developing the ability to protect motoneurons from injury-induced cell death and/or surviving motoneurons from secondary atrophy is an important goal. Our previous studies suggest that activation of phospholipase A 2 (PLA 2 ) may play an important role in mediating the secondary effects of SCI 7, 8 . The hydrolysis of membrane phospholipids by PLA 2 is a rate-limiting step for generation of pro-inflammatory mediators such as eicosanoids and platelet activating factor (PAF) [9] [10] [11] . The eicosanoids and PAF are well-known mediators of inflammation and tissue injury and have been implicated in pathological states of numerous acute and chronic neurological disorders 9, 10, 12 .
SCI significantly increased total PLA 2 activation and expression of cPLA 2 8 . Furthermore, 5 injured axons, glial cells, and neurons 13 . Administration of exogenous PLA 2 or melittin, a potent activator of endogenous PLA 2, resulted in cultured spinal neuronal death in a dose-dependent manner 8 . Importantly, such PLA 2 -or melittin-mediated neuronal death could be significantly reversed by inhibiting PLA 2 7, 8 , and inhibition of PLA 2 improved behavioral recovery after SCI in mice 13 . Thus, blocking PLA 2 activation may represent a novel strategy to reduce multiple damaging processes in the course of secondary SCI that leads to motoneuron atrophy.
To date, more than 27 isoforms of PLA 2 have been found in the mammalian system which can be classified into three major categories: secretory PLA 2 (sPLA 2 ), cytosolic PLA 2 (cPLA 2 ) and Ca 2+ -independent PLA 2 (iPLA 2 ) 11, 14 . Of these, cPLA 2 is the most important PLA 2 isozyme, and has been implicated as an effector in receptor-mediated release of arachidonic acid (AA) and exhibits strong preference for deacylation of AA over other fatty acids 9, 15 . Because cPLA 2 activation mediates Sema3A-induced growth cone collapse 16, 17 , it is possible that cPLA 2 activation is involved in dendritic atrophy after SCI. However, no studies to date have examined whether cPLA 2 has a role in motoneuron atrophy. In this study, we investigated the effects of cPLA 2 inhibition on spinal motoneurons and their target musculature after SCI.
Materials and methods
Female C57BL/6 mice (12 weeks) were purchased from Jackson Laboratories (Bar Harbor, ME). Female cPLA 2 -/-mice and wild-type (WT) littermates (12 weeks) generated from heterozygous breeding pairs at Indiana University School of Medicine Laboratory Animal
Resource Center were used in this study. The mice were maintained on a 12:12 light/dark cycle with food and water freely available. A total of 38 animals were used for the study and they were divided into 5 groups: sham-operated (n = 6), SCI (n = 8), SCI+ATK (n =8), wild-type SCI (n 
Injection of horseradish peroxidase conjugated to cholera toxin B subunit
Four weeks after injury, animals were re-anesthetized, and the left vastus lateralis muscle of the quadriceps was exposed and injected with horseradish peroxidase conjugated to the cholera toxin B subunit (BHRP; 0.5 µl, 0.2%; List Biological, Inc.). BHRP labeling permits populationlevel quantitative analysis of motoneuron somal and dendritic morphologies 24, 25 . Forty-eight hours after BHRP injection, a period that ensures optimal labeling of motoneurons 24, 25 , animals were weighed and received a lethal dose of Nembutal (60 mg/kg, i.p.), and were then perfused intracardially with saline followed by cold fixative (1% paraformaldehyde/1.25% glutaraldehyde).
Tissue processing, histology, and lesion assessments
A 12 mm thoracic spinal cord segment including the lesion was removed, postfixed overnight in the same fixative as used for perfusion, and transferred to sucrose phosphate buffer (30% w/v, pH 7.4). Thoracic segments were then embedded in gelatin, frozen, and sectioned transversely at 40 µm; alternate sections were collected into two series, and mounted on gelatin-coated slides.
One series was stained with cresyl violet and eosin for assessing lesion and spared tissue volume.
The cross-sectional areas of lesion or spared white and gray matter for each animal were measured in sections located 240 µm apart and spanning the entire rostrocaudal extent of the lesion using a video-based morphometry system (Stereo Investigator; MBF Bioscience, Williston, VT) at a final magnification of 202X. An unbiased estimation of the percentage of spared tissue was calculated using the Cavalieri method 26 . The total volume of spared white and gray matter was calculated by summing their individual subvolumes 27 . Individual subvolumes of spared tissue were calculated by multiplying the cross-sectional area A x d, where d represents the distance between sections (240 µm). The percent total volume of spared white and gray matter was calculated by dividing the total volume of spared white and gray matter by the total tissue volume of the corresponding region (x100), respectively. Estimation of total and percent total lesion volume was determined using identical procedures. The remaining series of thoracic sections were stained for myelin using Luxol fast blue as described previously 7 . The lesion area and total spinal cord area were outlined from a section through the lesion epicenter and sections located either 240 µm rostral or caudal to the epicenter using Stereo Investigator. The percent lesion area was determined by dividing the lesion area by the spinal cord area from the same section.
Motoneuron morphology and quantification
The vastus lateralis muscle is innervated by motoneurons located in column 3 of the lateral motor column in the L2 spinal segment [28] [29] [30] . Following perfusion, the lumbar portion of the spinal cord of each animal was removed, postfixed for 5 hours in the same fixative as used for perfusion, and then transferred to sucrose phosphate buffer (10% w/v, pH 7.4) overnight for cryoprotection. Spinal cords were then embedded in gelatin, frozen, and sectioned transversely at 40 µm; all sections were collected into 4 alternate series. One series was stained with thionin for use in cell counts. For visualization of BHRP, the 3 remaining series were immediately reacted using a modified tetramethyl benzidine protocol 5 , mounted on gelatin-coated slides, and counterstained with thionin. Motoneurons innervating the quadriceps muscles do not form a discrete nucleus, but instead are contained within the large continuous populations of motoneurons located within the lateral motor column. Thus, to identify the appropriate area within the lateral motor column for motoneuron counts in the unreacted series, we used a method similar to that of Little et al. 6 .
Briefly, for each animal the range of sections in which motoneurons labeled with BHRP after injection into the vastus lateralis muscle were present in the reacted series was identified, and then motoneuron counts were performed in the appropriate matching sections in the unreacted series. For each animal, estimates of the total number of motoneurons in the left and right lateral motor columns were obtained using the optical disector method previously described 6 defined by the actual distribution of BHRP-labeled somata from all of the animals used in the study) in each section within the identified range. Only motoneurons in which there was a clear nucleus and nucleolus were counted, provided they did not contact the forbidden lines of the counting frame; motoneuron nucleoli were counted as they appeared while focusing through the z axis, and nucleoli in the first focal plane (i.e., "tops") were excluded to avoid double counting.
Motoneuron counts were derived from a mean of 5.33 sections spaced 480 µm apart and distributed uniformly through the entire rostrocaudal extent of the quadriceps motoneuron pool range. Cell counts for each animal were corrected for the proportion of sections sampled.
Using similar methods, the number of BHRP-labeled motoneurons was assessed in all sections of the reacted series through the entire rostrocaudal extent of their distribution for all animals. Counts of labeled quadriceps motoneurons were made under brightfield illumination, where somata could be visualized and cytoplasmic inclusion of BHRP reaction product confirmed.
Soma volume
The volume of quadriceps motoneuron somata was assessed in at least one set of alternate sections (160 µm apart) using the Nucleator method 31 . A set of 4 rays emanating from a point randomly chosen within each BHRP-labeled motoneuron soma was drawn and oriented randomly. Soma volumes of an average of 28.1 motoneurons were measured for each animal using Stereo Investigator at a final magnification of 780X. Soma volumes within each animal were then averaged for statistical analysis.
Dendritic length
For each animal, dendritic lengths in a single representative set of alternate sections were measured under darkfield illumination. Beginning with the first section in which BHRP-labeled fibers were present, labeling through the entire rostrocaudal extent of the quadriceps motoneuron dendritic field was assessed in every third section (480 µm apart) in three dimensions using a computer-based morphometry system (Neurolucida; MBF Bioscience, Williston, VT) at a final magnification of 250X. Average dendritic length per labeled motoneuron was estimated by summing the measured dendritic lengths of the series of sections, multiplying by three to correct for sampling, then dividing by the total number of labeled motoneurons in that series. This method does not attempt to assess the actual total dendritic length of labeled motoneurons 32 , but has been shown to be a sensitive and reliable indicator of changes in dendritic morphology in This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Downloaded by Indiana Univ Acq Dept from online.liebertpub.com at 09/05/17. For personal use only.
normal development 24, 33, 34 , after changes in dendritic interactions 33 and afferent input [35] [36] [37] , and after injury 6, [21] [22] [23] 38 .
Dendritic distribution
To assess potential redistributions of dendrites across treatment groups, for each animal the composite dendritic arbor created in the length analysis was divided using a set of axes oriented radially around the center of the collective labeled somata. These axes divided the spinal cord into 12 bins of 30° each. The portion of each animal's dendritic arbor per labeled motoneuron contained within each location was then determined. This method provides a sensitive measure of dendritic redistribution in response to changes in dendritic interactions 33 and afferent input 35, 36 .
Dendritic extent
The comparability of BHRP labeling across groups was assessed by quantifying both the rostrocaudal and the radial extent of quadriceps motoneuron dendritic arbors. The rostrocaudal extent of the dendritic arbor was determined by recording the rostrocaudal distance spanned by quadriceps motoneuron dendrites for each animal. The maximal radial extent of the arbor in the transverse plane was also measured for each animal, using a set of axes oriented radially around the center of the collective labeled somata. These axes divided the spinal cord into 12 bins of 30° each. For each bin, the linear distance between the center of the quadriceps motor pool and the most distal BHRP-filled process was measured. Radial dendritic extent is independent of overall dendritic length and reflects the maximal linear distance (in the transverse plane) of BHRP transport to the most distal dendritic processes. 
Muscle fiber and motor endplate morphology
The right vastus lateralis muscles were removed immediately after perfusion and weighed.
Muscles were then postfixed overnight in the same fixative as used for perfusion, and then transferred to sucrose phosphate buffer (10% w/v, pH 7.4). Muscles were then rinsed in distilled water, blocked into proximal and distal segments, and flash-frozen in 2-methylbutane. Muscle segments were then sectioned (45 µm) either transversely (for examination of muscle fiber crosssectional area) or longitudinally (for examination of motor endplate area and density) on a cryostat at -20° C and thaw-mounted onto glass slides. Muscle fiber cross-sectional area was assessed after staining with Milligan's trichrome stain. Motor endplate size and density were assessed after staining for acetylcholinesterase using the Roots-Karnovsky method 39 . Crosssectional muscle fiber area and motor endplate size were measured under brightfield illumination 
Statistical analysis
All data are presented as mean ± SEM and were analyzed by t-tests or analyses of variance (one way, two way, or repeated measures as appropriate) followed by post hoc analyses using Fisher's least significant difference (LSD). Digital light micrographs were obtained using an MDS 290 digital camera system (Eastman Kodak Company, Rochester, NY). Brightness and contrast of these images were adjusted in Adobe Photoshop (Adobe Systems, San Jose, CA).
Results

Lesion volume and white matter sparing
Contusive SCI resulted in large lesion with thin rims of spared tissue ( Importantly, despite the large size of the lesions, they did not extend into the L2 level, and thus did not compromise the quadriceps motoneuron populations directly. 
Dendritic extent
Consistent with the nonuniform dendritic distribution of quadriceps motoneurons apparent in Figure 2 , radial dendritic extent differed across bins (Fig. 3C) , and repeated-measures ANOVA revealed a significant effect of location [F (11, 198 weights of the vastus lateralis muscles in SCI+ATK animals (0.067 ± 0.002 g) were 31.4% larger than those of SCI+vehicle animals (LSD p < .0001), and did not differ from those of sham animals (LSD, ns).
Muscle fiber size was also affected by contusion injury (Fig. 4C) 
Discussion
In this study, we found that ATK treatment can completely prevent pronounced dendritic atrophy in spinal motoneurons caudal to a contusive SCI, indicating a protective role of cPLA 2 inhibition on prevention of motoneuron dendritic degeneration after SCI. Genetic deletion of cPLA 2 significantly reduced dendritic atrophy after SCI. It should be noted that after SCI, motoneurons caudal to the injury are morphologically intact and are not directly traumatized by the injury. Inhibition of cPLA 2 also prevented decreases in the weights of the target musculature.
To our knowledge, this is the first study demonstrating a neuroprotective effect of cPLA 2 inhibition on motoneuron dendritic degenerative change and muscle morphology following SCI.
Such injury induced secondary effect on motoneurons and associated musculature remote to the injury itself may provide new targets for therapeutical interventions aimed at enhancing recovery of functional after SCI. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Downloaded by Indiana Univ Acq Dept from online.liebertpub.com at 09/05/17. For personal use only.
Mouse SCI models are being increasingly used because transgenic and knockout mice are available for the study of cellular mechanisms. Certain mouse strains, such as C57BL/6, 129/Sv, and B10.rIII, have a naturally occurring null mutation of the major form of sPLA 2 40 . Therefore, C57BL/6 mice in this study were deficient in sPLA 2 . ATK is a potent and selective inhibitor of cPLA 2 . This inhibitor shows slow tight binding to cPLA 2 in the presence of Ca 2+ and forms a covalent bond with a serine residue in the active site of the enzyme 19, 41 . This inhibitor is about 500-fold more potent at inhibiting cPLA 2 than sPLA 2 19 and may also be a weak inhibitor of iPLA 2 42-44 .
Following contusion, the focal injuries delivered to the spinal cord developed into large lesions that spanned multiple thoracic spinal segments. Such lesions were significantly reduced by ATK treatment. Notably, the cPLA 2 inhibitor was administered after trauma, modeling a clinically relevant situation. These findings are in agreement with our previous studies that inhibition of PLA 2 reduced tissue damage and increased spared white matter after SCI 7, 13 .
Several other studies also reported a detrimental effect of cPLA 2 in other CNS diseases such as ischemia 45, 46 , experimental autoimmune encephalomyelitis 20, 47 and Alzheimer's disease 48 .
Our previous studies showed that SCI significantly induced cPLA 2 activation, which was observed as early as 8 h post-injury and peaked at 7 d post-injury. The activated cPLA 2 was mainly localized in neurons and oligodendrocytes. It has also been shown that arachidonic acid (AA) and eicosanoids, downstream metabolites of cPLA 2 , increased as early as 30 min after SCI 49, 50 . The increased eicosanoids were persistent for at least 3 d (the longest time point studied)
after SCI 51 . In addition, concentrations of free fatty acid quickly increased after SCI, peaked at 3 d, and remained significantly high at 7 d after SCI 52 . Since the induction profiles of these PLA 2 metabolites are similar to that of cPLA 2 after SCI, a prolonged effect of cPLA 2 after SCI exists, This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Downloaded by Indiana Univ Acq Dept from online.liebertpub.com at 09/05/17. For personal use only.
suggesting that there might be a unique "therapeutic window" for intervention. Although cPLA 2 inhibitor in the present study was administered for two weeks after trauma, the optimal therapeutic time window for such treatment remains to be determined. observed reductions throughout the arbor, but again the reductions were greatest in the ventromedial portion of the dendritic distribution. This loss is of particular significance after SCI, as descending reticulospinal fibers course through the ventral and lateral funiculi 57, 58 , and disruption of these tracts results in hindlimb motor deficits 59, 60 . Therefore, it is possible that the dendritic atrophy we observed following SCI in untreated animals could reflect deafferentation resulting from the loss of descending motor and propriospinal tracts.
Changes in motoneuron morphology are not direct effects of lesion
Inhibition of cPLA 2 attenuates SCI-induced motoneuron dendritic atrophy
SCI-induced atrophy of quadriceps motoneuron dendrites was attenuated in ATK-treated animals. Genetic deletion of cPLA 2 also resulted in neuroprotection on dendritic atrophy after SCI. However, mechanisms of cPLA 2 inhibition-mediated motoneuron atrophy remain unclear.
One possibility is that ATK treatment could have attenuated dendritic atrophy by increasing the number of spared axons that traverse the lesion, which is consistent with the reduction in lesion size and corresponding increase in white matter sparing. The other possibility is that cPLA 2 may have a direct effect on dendrites. Such a direct effect is supported by other reports that cPLA 2 activation mediates Sema3A-induced growth cone collapse 16, 17 , suggesting that cPLA 2 activation could be directly involved in dendritic retraction after SCI. The attenuation in dendritic atrophy we observed in ATK-treated animals could potentially maintain motor activation and account for the protective effects of ATK on locomotor function we have observed 13 . Such an effect would lead to protection of the target musculature from disuse atrophy and could support exercise training effects on locomotor function after SCI 61, 62 . We believe that the differences we observed across treatment groups reflect true dendritic atrophy in quadriceps motoneurons of untreated SCI animals, which is attenuated by treatment with ATK. However, the possibility that confounding changes arising from SCI could affect retrograde transport is an important consideration, as such an artifact could potentially result in apparent alterations in dendritic morphology. However, no differences in either radial or rostrocaudal extents of quadriceps motoneuron dendrites in the SCI groups compared to normal values were observed. Therefore, we believe that the dendritic labeling across groups was comparable and that the shorter dendritic lengths we observed in the untreated SCI animals reflect true dendritic atrophy.
Comparability of BHRP labeling
Muscle atrophy after SCI
The regressive changes we observed in muscle weight and fiber diameter are typical after SCI in muscles innervated by motoneurons below the level of the lesion, especially in weightbearing muscles such as the quadriceps 63, 64 . This atrophy can result from either denervation due to loss of motoneurons or damage to the ventral roots, or disuse consequent to decreases in muscle activation potentially due to the loss of synaptic input to remaining motoneurons 65 . In the current study, the atrophy we observed cannot be ascribed to an effect of denervation, as we observed no changes in quadriceps motoneuron number, the number of BHRP-labeled quadriceps motoneurons, or the sizes or densities of motor endplates between sham animals and untreated SCI animals. Thus, the decreased weight and fiber size we observed most likely reflect a disuse atrophy, potentially resulting after damage to descending and propriospinal projections and/or the reductions in quadriceps motoneuron dendritic length we observed. Such reductions in quadriceps motoneuron dendritic length result in attenuation of motor activation, reducing response amplitudes in the femoral nerve generated by dorsal root afferent stimulation 6 .
Alternatively, disuse atrophy may also result from changes in muscle length or loading conditions that could decrease protein synthesis and increase protein degradation 66, 67 .
Protection of muscle with ATK
In the current study, ATK treatment prevented the atrophy in muscle weight seen after SCI.
However, there is no significant difference in muscle fiber area between the SCI and SCI + ATK treatment group. The reason for the reversal of muscle weight loss without changing of muscle fiber size is unclear. The protection of muscle weight could be the result of a sparing of motoneuron function. As described above, ATK treatment can reverse the regressive changes in dendritic morphology and motor activation. Thus, the protection from dendritic atrophy with ATK treatment after SCI could have spared local spinal circuitry sufficiently to maintain motor activation and use leg more for walking, preventing disuse atrophy of the target muscles.
Conclusions
The present results indicate that the regressive changes in motoneuron and muscle morphology seen after SCI can be prevented by blocking cPLA 2 pharmacologically at 30 min post-injury or genetically deleting cPLA 2 in mice, potentially providing a mechanism for the improved locomotor performance previously observed with cPLA 2 inhibitor treatments following SCI. Together, these results further support a role for cPLA 2 as a therapeutic target for treatment of SCI. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Downloaded by Indiana Univ Acq Dept from online.liebertpub.com at 09/05/17. For personal use only.
